Developing CAR T for Solid Tumours: Interview with John Bridgeman, ImmunoKey
John Bridgeman
Chief Scientific Officer
ImmunoKey
Format: 11 Minute Interview
Register free to attend thought leadership
Do you have a question you’d like John Bridgeman to answer during the session?
Register and askRelated posts
Animal Free 3D Cell Culture and Organoid Growth: Interview with Aline Miller, University of Manchester
Developing CAR T for Solid Tumours: Interview with John Bridgeman, ImmunoKey
Designing Next-Gen Biomaterials: Peptide Hydrogels in 3D Culture & Regenerative Platforms
Commissioning ATMPs for the NHS: Interview with Sarah McAleer & Kiran Moyo, NHS England
Centralised Off-The-Shelf Cell Therapies: Interview with Volker Huppert, Glycostem
Upcoming events
Cell 2025
In-Person
Welcome to Cell 2025, Oxford Global’s flagship event, serving as the ultimate meeting place for bioprocessing and advanced therapy professionals. This event brings together leaders from pharma, biotech, academia, and regulatory institutions across the entire cell culture and cell & gene therapy value chain.
Identification, Validation & Exploration Of Novel Targets In Immuno-Oncology
Online
This tech showcase will feature cutting-edge content on high-throughput screening approaches, in vitro and in vivo models, and emerging modalities for new targets. Attendees will have the opportunity to see the latest technology innovations in action, followed by a live discussion with industry experts to explore real-world applications and challenges.
Register for free to view
-
Quickly grasp the key takeaways from cutting-edge biomed research with our bite-sized 5-minute video summaries, before diving into the full presentations from leaders in the industry.
-
From cutting-edge discoveries to real-world applications, see how new research can impact your work, from the lab to commercialisation.
-
Join a community of next-gen scientists, academics and researchers, stay connected, and engage with the latest innovations shaping the future of biomedicine.
Already registered? Sign In.